20 names are moving together; 65% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| SNGX | Soligenix, Inc. | Healthcare | +6.2% | Group member |
| TXG | 10x Genomics, Inc. | Healthcare | +9.5% | Group member |
| TEO | Telecom Argentina SA | Communication Services | +2.6% | Group member |
| GGAL | Grupo Financiero Galicia S.A. | Financial Services | -1.3% | Group member |
| AGI | Alamos Gold Inc. | Basic Materials | +1.8% | Group member |
| HZO | MarineMax, Inc. (FL) | Consumer Cyclical | -0.2% | Group member |
| ARTV | Artiva Biotherapeutics, Inc. | Healthcare | +4.6% | Group member |
| KSPI | Joint Stock Company Kaspi.kz - | Technology | +0.6% | Group member |
| GLUE | Monte Rosa Therapeutics, Inc. | Healthcare | +6.7% | Group member |
| BLLN | BillionToOne, Inc. | Healthcare | +1.1% | Group member |
| CGC | Canopy Growth Corporation | Healthcare | -0.8% | Group member |
| JANX | Janux Therapeutics, Inc. | Healthcare | -2.2% | Group member |
| CLRB | Cellectar Biosciences, Inc. | Healthcare | +1.1% | Group member |
| VOR | Vor Biopharma Inc. | Healthcare | +2.4% | Group member |
| DBD | Diebold Nixdorf Incorporated | Technology | -0.1% | Group member |
| BA | Boeing Company (The) | Industrials | +0.8% | Group member |
| SLDB | Solid Biosciences Inc. | Healthcare | -1.3% | Group member |
| MAZE | Maze Therapeutics, Inc. | Healthcare | +2.5% | Group member |
| CORT | Corcept Therapeutics Incorporat | Healthcare | +5.2% | Most structurally connected |
| WRBY | Warby Parker Inc. | Healthcare | +0.7% | Group member |
Cohort
20 namesParticipation
65% this sessionObserved history
1 daily buildsFiling coverage
16/20 membersrestructuring
“If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.”
CORT 10-K
restructuring affecting expense
“The lower expense was partially offset by an increase in operating loss relating to impairment restructuring charges relating primarily to the impairment of goodwill.”
CGC 10-K
product pipeline / R&D affecting expense
“The increase of $2.3 million was primarily due to a $2.4 million increase in external research and development expense, partially offset by a $0.1 million decrease in internal research and development expense.”
ARTV 10-Q
Cross-asset confirmation is still fragile, so spillover can stall before it becomes durable.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.